The Library

Germinal and somatic trisomy 21 mosaicism : how common is it, what are the implications for individual carriers and how does it come about?

Tools

Hultén, Maj A., Jonasson, Jon, Nordgren, Ann and Iwarsson, Erik. (2010) Germinal and somatic trisomy 21 mosaicism : how common is it, what are the implications for individual carriers and how does it come about? Current Genomics, Vol.11 (No.6). pp. 409-419. ISSN 1389-2029

Preview

PDF
WRAP_Hulten_Germinal_somatic_trisomy.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Available under License Creative Commons Attribution.
Download (304Kb)

Official URL: http://dx.doi.org/10.2174/138920210793176056

Abstract

It is well known that varying degrees of mosaicism for Trisomy 21, primarily a combination of normal and Trisomy 21 cells within individual tissues, may exist in the human population. This involves both Trisomy 21 mosaicism occurring in the germ line and Trisomy 21 mosaicism documented in different somatic tissues, or indeed a combination of both in the same subjects. Information on the incidence of Trisomy 21 mosaicism in different tissue samples from people with clinical features of Down syndrome as well as in the general population is, however, still limited. One of the main reasons for this lack of detailed knowledge is the technological problem of its identification, where in particular low grade/cryptic Trisomy 21 mosaicism, i.e. occurring in less than 3-5% of the respective tissues, can only be ascertained by fluorescence in situ hybridization (FISH) methods on large cell populations from the different tissue samples. In this review we summarize current knowledge in this field with special reference to the question on the likely incidence of germinal and somatic Trisomy 21 mosaicism in the general population and its mechanisms of origin. We also highlight the reproductive and clinical implications of this type of aneuploidy mosaicism for individual carriers. We conclude that the risk of begetting a child with Trisomy 21 Down syndrome most likely is related to the incidence of Trisomy 21 cells in the germ line of any carrier parent. The clinical implications for individual carriers may likewise be dependent on the incidence of Trisomy 21 in the relevant somatic tissues. Remarkably, for example, there are indications that Trisomy 21 mosaicism will predispose carriers to conditions such as childhood leukemia and Alzheimer's Disease but there is on the other hand a possibility that the risk of solid cancers may be substantially reduced.

Item Type:	Journal Article
Subjects:	Q Science > QH Natural history > QH426 Genetics
Divisions:	Faculty of Medicine > Warwick Medical School > Reproductive Health Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Mosaicism, Down syndrome
Journal or Publication Title:	Current Genomics
Publisher:	Bentham Science Publishers Ltd.
ISSN:	1389-2029
Date:	September 2010
Volume:	Vol.11
Number:	No.6
Number of Pages:	11
Page Range:	pp. 409-419
Identification Number:	10.2174/138920210793176056
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
References:	[1] Kovaleva, N.V. Germ-line transmission of trisomy 21: Data from 80 families suggest an implication of grandmaternal age and a high frequency of female-specific trisomy rescue. Mol. Cytogenet., 2010, 3, 7. [2] Gautier, M.; Harper, P.S. Fiftieth anniversary of trisomy 21: returning to a discovery. Hum. Genet., 2009, 126, 317-324. [3] Jacobs, P.A.; Baikie, A.G.; Court Brown, W.M.; Strong, J.A. The somatic chromosomes in mongolism. Lancet, 1959, 1, 710. [4] Katznelson, M.B.; Bejerano, M.; Yakovenko, K.; Kobyliansky, E. Relationship between genetic anomalies of different levels and deviations in dermatoglyphic traits. Part 4: Dermatoglyphic peculiarities of males and females with Down syndrome. Family study. Anthropol. Anz., 1999, 57, 193-255. [5] Kücken, M. Models for fingerprint pattern formation. Forensic Sci. Int., 2007, 171, 85-96. [6] Lejeune, J.; Turpin, R.; Gautier, M. Mongolism; a chromosomal disease (trisomy). Bull. Acad. Natl. Med., 1959, 143, 256-265. [7] Mardia, K.V.; Li, Q.; Hainsworth, T.J. On the Penrose hypothesis on fingerprint patterns. IMA J. Math. Appl. Med. Biol., 1992, 9, 289-294. [8] Penrose, L.S. The distal triradius t on the hands of parents and sibs of mongol imbeciles. Ann. Hum. Genet., 1954, 19, 10-38. [9] Berkova, A.; Zemanova, Z.; Trneny, M.; Schwarz, J.; Karban, J.; Cmunt, E.; Pavlistova, L.; Brezinova, J.; Michalova, K. Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization. Neoplasma, 2009, 56, 455-458. [10] de Arruda Cardoso Smith, M.; Borsatto-Galera, B.; Feller, R.I.; Goncalves, A.; Oyama, R.S.; Segato, R.; Chen, E.; Carvalheira, G.M.; Filho, A.S.; Burbano, R.R.; Payao, S.L. Telomeres on chromosome 21 and aging in lymphocytes and gingival fibroblasts from individuals with Down syndrome. J. Oral. Sci., 2004, 46, 171-177. [11] DeUgarte, C.M.; Li, M.; Surrey, M.; Danzer, H.; Hill, D.; DeCherney, A.H. Accuracy of FISH analysis in predicting chromosomal status in patients undergoing preimplantation genetic diagnosis. Fertil. Steril., 2008, 90, 1049-1054. [12] Hultén, M.A.; Dhanjal, S.; Pertl, B. Rapid and simple prenatal diagnosis of common chromosome disorders: advantages and disadvantages of the molecular methods FISH and QF-PCR. Reproduction, 2003, 126, 279-297. [13] Iourov, I.Y.; Soloviev, I.V.; Vorsanova, S.G.; Monakhov, V.V.; Yurov, Y.B. An approach for quantitative assessment of fluorescence in situ hybridization (FISH) signals for applied human molecular cytogenetics. J. Histochem. Cytochem., 2005, 53, 401- 408. [14] Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Intercellular Genomic (Chromosomal) Variations Resulting in Somatic Mosaicism: Mechanisms and Consequences. Curr. Genomics, 2006, 7, 435- 446. [15] Lomax, B.L.; Kalousek, D.K.; Kuchinka, B.D.; Barrett, I.J.; Harrison, K.J.; Safavi, H. The utilization of interphase cytogenetic analysis for the detection of mosaicism. Hum. Genet., 1994, 93, 243-247. [16] Modi, D.; Berde, P.; Bhartiya, D. Down syndrome: a study of chromosomal mosaicism. Reprod. Biomed. Online, 2003, 6, 499- 503. [17] Shi, Q.; Adler, I.D.; Zhang, J.; Zhang, X.; Shan, X.; Martin, R. Incidence of mosaic cell lines in vivo and malsegregation of chromosome 21 in lymphocytes in vitro of trisomy 21 patients: detection by fluorescence in situ hybridization on binucleated lymphocytes. Hum. Genet., 2000, 106, 29-35. [18] Shi, Q.; Chen, J.; Adler, I.; Zhang, J.; Martin, R.; Pan, S.; Zhang, X.; Shan, X. Increased nondisjunction of chromosome 21 with age in human peripheral lymphocytes. Mutat. Res., 2000, 452, 27-36. [19] Vorsanova, S.G.; Yurov, Y.B.; Iourov, I.Y. Human interphase chromosomes: a review of available molecular cytogenetic technologies. Mol. Cytogenet., 2010, 3, 1. [20] Hook, E.B. Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use. Am. J. Hum. Genet., 1977, 29, 94-97. [21] Hultén, M.A.; Gould, C.P.; Goldman, A.S.; Waters, J.J. Chromosome in situ suppression hybridisation in clinical cytogenetics. J. Med. Genet., 1991, 28, 577-582. [22] Iourov, I.Y.; Liehr, T.; Vorsanova, S.G.; Yurov, Y.B. Interphase chromosome-specific multicolor banding (ICS-MCB): a new tool for analysis of interphase chromosomes in their integrity. Biomol. Eng., 2007, 24, 415- 417. [23] Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Chromosomal mosaicism goes global. Mol. Cytogenet., 2008, 1, 26. [24] Hultén, M.A.; Patel, S.D.; Tankimanova, M.; Westgren, M.; Papadogiannakis, N.; Jonsson, A.M.; Iwarsson, E. On the origin of trisomy 21 Down syndrome. Mol. Cytogenet., 2008, 1, 21. [25] Hultén, M.A.; Patel, S.; Jonasson, J.; Iwarsson, E. On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model. Reproduction, 2010, 139, 1-9. [26] Cui, Y.X.; Hao, L.J.; Wang, Y.H.; Xia, X.Y.; Shi, Y.C.; Lu, H.Y.; Yao, B.; Huang, Y.F. Second pregnancy of trisomy 21 in a mother with mosaicism. Chin. Med. J. (Engl), 2007, 120, 1295-1296. [27] De Souza, E.; Halliday, J.; Chan, A.; Bower, C.; Morris, J.K. Recurrence risks for trisomies 13, 18, and 21. Am. J. Med. Genet. A, 2009, 149A, 2716-2722. [28] James, R.S.; Ellis, K.; Pettay, D.; Jacobs, P.A. Cytogenetic and molecular study of four couples with multiple trisomy 21 pregnancies. Eur. J. Hum. Genet., 1998, 6, 207-212. [29] Migliore, L.; Migheli, F.; Coppede, F. Susceptibility to aneuploidy in young mothers of Down syndrome children. ScientificWorldJournal, 2009, 9, 1052-1060. [30] Hultén, M.A.; Patel, S.D.; Westgren, M.; Papadogiannakis, N.; Jonsson, A.M.; Jonasson, J.; Iwarsson, E. On the paternal origin of trisomy 21 Down syndrome. Mol. Cytogenet., 2010, 3, 4. [31] Gazvani, M.R.; Wilson, E.D.; Richmond, D.H.; Howard, P.J.; Kingsland, C.R.; Lewis-Jones, D.I. Role of mitotic control in spermatogenesis. Fertil. Steril., 2000, 74, 251-256. [32] Jacobs, P.A. The chromosome complement of human gametes. Oxf. Rev. Reprod. Biol., 1992, 14, 47-72. [33] Rubes, J.; Vozdova, M.; Oracova, E.; Perreault, S.D. Individual variation in the frequency of sperm aneuploidy in humans. Cytogenet. Genome Res., 2005, 111, 229-236. [34] Rubes, J.; Vozdova, M.; Robbins, W.A.; Rezacova, O.; Perreault, S.D.; Wyrobek, A.J. Stable variants of sperm aneuploidy among healthy men show associations between germinal and somatic aneuploidy. Am. J. Hum. Genet., 2002, 70, 1507-1519. [35] Sarrate, Z.; Vidal, F.; Blanco, J. Role of sperm fluorescent in situ hybridization studies in infertile patients: indications, study approach, and clinical relevance. Fertil. Steril., 2010, 93, 1892-1902. [36] Soares, S.R.; Templado, C.; Blanco, J.; Egozcue, J.; Vidal, F. Numerical chromosome abnormalities in the spermatozoa of the fathers of children with trisomy 21 of paternal origin: generalised tendency to meiotic non- disjunction. Hum. Genet., 2001, 108, 134- 139. [37] Tempest, H.G.; Ko, E.; Rademaker, A.; Chan, P.; Robaire, B.; Martin, R.H. Intra-individual and inter- individual variations in sperm aneuploidy frequencies in normal men. Fertil. Steril., 2009, 91, 185-192. [38] Young, S.S.; Eskenazi, B.; Marchetti, F.M.; Block, G.; Wyrobek, A.J. The association of folate, zinc and antioxidant intake with sperm aneuploidy in healthy non-smoking men. Hum. Re- prod., 2008, 23, 1014-1022. [39] Aït Yahya-Graison, E.; Aubert, J.; Dauphinot, L.; Rivals, I.; Prieur, M.; Golfier, G.; Rossier, J.; Personnaz, L.; Creau, N.; Blehaut, H.; Robin, S.; Delabar, J.M.; Potier, M.C. Classification of human chromosome 21 gene- expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet., 2007, 81, 475- 491. [40] Antonarakis, S.E.; Lyle, R.; Dermitzakis, E.T.; Reymond, A.; Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet., 2004, 5, 725-738. [41] Dierssen, M.; Herault, Y.; Estivill, X. Aneuploidy: from a physiological mechanism of variance to Down syndrome. Physiol. Rev., 2009, 89, 887-920. [42] Korenberg, J.R.; Chen, X.N.; Schipper, R.; Sun, Z.; Gonsky, R.; Gerwehr, S.; Carpenter, N.; Daumer, C.; Dignan, P.; Disteche, C.; et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl. Acad. Sci. USA, 1994, 91, 4997-5001. [43] Patterson, D. Molecular genetic analysis of Down syndrome. Hum. Genet., 2009, 126, 195-214. [44] Bornstein, E.; Lenchner, E.; Donnenfeld, A.; Kapp, S.; Keeler, S.M.; Divon, M.Y. Comparison of modes of ascertainment for mosaic vs complete trisomy 21. Am. J. Obstet. Gynecol., 2009, 200, 440 e441 -445. [45] Papavassiliou, P.; York, T.P.; Gursoy, N.; Hill, G.; Nicely, L.V.; Sundaram, U.; McClain, A.; Aggen, S.H.; Eaves, L.; Riley, B.; Jackson-Cook, C. The phenotype of persons having mosaicism for trisomy 21/Down syndrome reflects the percentage of trisomic cells present in different tissues. Am. J. Med. Genet. A, 2009, 149A, 573- 583. [46] Ringman, J.M.; Younkin, S.G.; Pratico, D.; Seltzer, W.; Cole, G.M.; Geschwind, D.H.; Rodriguez-Agudelo, Y.; Schaffer, B.; Fein, J.; Sokolow, S.; Rosario, E.R.; Gylys, K.H.; Varpetian, A.; Medina, L.D.; Cummings, J.L. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology, 2008, 71, 85-92. [47] Sherman, S.L.; Allen, E.G.; Bean, L.H.; Freeman, S.B. Epidemiology of Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev., 2007, 13, 221-227. [48] Shin, M.; Siffel, C.; Correa, A. Survival of children with mosaic Down syndrome. Am. J. Med. Genet. A, 2010, 152A, 800-801. [49] Sifakis, S.; Koukoura, O.; Mantas, N.; Velissariou, V.; Koumantakis, E. Hydrops fetalis, thickened placenta and other sonographic findings in a low-level trisomy 21 mosaicism: a case report. Fetal. Diagn. Ther., 2008, 24, 310-312. [50] Devlin, L.; Morrison, P.J. Mosaic Down's syndrome prevalence in a complete population study. Arch. Dis. Child., 2004, 89, 1177- 1178. [51] Yurov, Y.B.; Vorsanova, S.G.; Iourov, I.Y. GIN'n'CIN hypothesis of brain aging: deciphering the role of somatic genetic instabilities and neural aneuploidy during ontogeny. Mol. Cytogenet., 2009, 2, 23. [52] Bergholdt, R.; Eising, S.; Nerup, J.; Pociot, F. Increased prevalence of Down's syndrome in individuals with type 1 diabetes in Denmark: A nationwide population-based study. Diabetologia, 2006, 49, 1179-1182. [53] Kusters, M.A.; Gemen, E.F.; Verstegen, R.H.; Wever, P.C.; de Vries, E. Both normal memory counts and decreased naive cells favor intrinsic defect over early senescence of Down syndrome Tlymphocytes. Pediatr. Res., 2010. [54] Fonatsch, C. The role of chromosome 21 in hematology and oncology. Genes Chromosomes Cancer, 2010, [Epub ahead of print]. [55] Rabin, K.R.; Whitlock, J.A. Malignancy in children with trisomy 21. Oncologist, 2009, 14, 164-173. [56] Xavier, A.C.; Ge, Y.; Taub, J.W. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J. Mol. Diagn., 2009, 11, 371- 380. [57] Andersson, A.; Olofsson, T.; Lindgren, D.; Nilsson, B.; Ritz, C.; Eden, P.; Lassen, C.; Rade, J.; Fontes, M.; Morse, H.; Heldrup, J.; Behrendtz, M.; Mitelman, F.; Hoglund, M.; Johansson, B.; Fioretos, T. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc. Natl. Acad. Sci. USA, 2005, 102, 19069-19074. [58] Bercovich, D.; Ganmore, I.; Scott, L.M.; Wainreb, G.; Birger, Y.; Elimelech, A.; Shochat, C.; Cazzaniga, G.; Biondi, A.; Basso, G.; Cario, G.; Schrappe, M.; Stanulla, M.; Strehl, S.; Haas, O.A.; Mann, G.; Binder, V.; Borkhardt, A.; Kempski, H.; Trka, J.; Bielorei, B.; Avigad, S.; Stark, B.; Smith, O.; Dastugue, N.; Bourquin, J.P.; Tal, N.B.; Green, A.R.; Izraeli, S. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet, 2008, 372, 1484-1492. [59] Chokkalingam, A.P.; Buffler, P.A. Genetic susceptibility to childhood leukaemia. Radiat. Prot. Dosimetry, 2008, 132, 119-129. [60] Ganmore, I.; Smooha, G.; Izraeli, S. Constitutional aneuploidy and cancer predisposition. Hum. Mol. Genet., 2009, 18, R84-93. [61] Hertzberg, L.; Vendramini, E.; Ganmore, I.; Cazzaniga, G.; Schmitz, M.; Chalker, J.; Shiloh, R.; Iacobucci, I.; Shochat, C.; Zeligson, S.; Cario, G.; Stanulla, M.; Strehl, S.; Russell, L.J.; Harrison, C.J.; Bornhauser, B.; Yoda, A.; Rechavi, G.; Bercovich, D.; Borkhardt, A.; Kempski, H.; te Kronnie, G.; Bourquin, J.-P.; Domany, E.; Izraeli, S. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood, 2010, 115, 1006-1017. [62] Johansson, B.; Harrison, C.J., Acute myeloid leukemia. In: Cancer Cytogenetics, 3rd ed.; Heim, S.; Mitelman, F., Eds. Wiley- Blackwell: Hoboken, 2009; pp 45-139. [63] Karrman, K.; Forestier, E.; Andersen, M.K.; Autio, K.; Borgstrom, G.; Heim, S.; Heinonen, K.; Hovland, R.; Kerndrup, G.; Johansson, B. High incidence of the ETV6/RUNX1 fusion gene in paediatric precursor B-cell acute lymphoblastic leukaemias with trisomy 21 as the sole cytogenetic change: a Nordic series of cases diagnosed 1989-2005. Br. J. Haematol., 2006, 135, 352-354. [64] Kearney, L.; Gonzalez De Castro, D.; Yeung, J.; Procter, J.; Horsley, S.W.; Eguchi-Ishimae, M.; Bateman, C.M.; Anderson, K.; Chaplin, T.; Young, B.D.; Harrison, C.J.; Kempski, H.; So, C.W.; Ford, A.M.; Greaves, M. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood, 2009, 113, 646-648. [65] Klusmann, J.H.; Li, Z.; Bohmer, K.; Maroz, A.; Koch, M.L.; Emmrich, S.; Godinho, F.J.; Orkin, S.H.; Reinhardt, D. miR125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev., 2010, 24, 478-490. [66] Korbel, J.O.; Tirosh-Wagner, T.; Urban, A.E.; Chen, X.N.; Kasowski, M.; Dai, L.; Grubert, F.; Erdman, C.; Gao, M.C.; Lange, K.; Sobel, E.M.; Barlow, G.M.; Aylsworth, A.S.; Carpenter, N.J.; Clark, R.D.; Cohen, M.Y.; Doran, E.; Falik-Zaccai, T.; Lewin, S.O.; Lott, I.T.; McGillivray, B.C.; Moeschler, J.B.; Pettenati, M.J.; Pueschel, S.M.; Rao, K.W.; Shaffer, L.G.; Shohat, M.; Van Riper, A.J.; Warburton, D.; Weissman, S.; Gerstein, M.B.; Snyder, M.; Korenberg, J.R. The genetic architecture of Down syndrome phenotypes revealed by high- resolution analysis of human segmental trisomies. Proc. Natl. Acad. Sci. USA, 2009, 106, 12031-12036. [67] Malinge, S.; Izraeli, S.; Crispino, J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 2009, 113, 2619-2628. [68] Minelli, A.; Morerio, C.; Maserati, E.; Olivieri, C.; Panarello, C.; Bonvini, L.; Leszl, A.; Rosanda, C.; Lanino, E.; Danesino, C.; Pasquali, F. Meiotic origin of trisomy in neoplasms: evidence in a case of erythroleukaemia. Leukemia, 2001, 15, 971- 975. [69] Mitelman, F.; Heim, S.; Mandahl, N. Trisomy 21 in neoplastic cells. Am. J. Med. Genet. Suppl., 1990, 7, 262-266. [70] Tsuzuki, S.; Karnan, S.; Horibe, K.; Matsumoto, K.; Kato, K.; Inukai, T.; Goi, K.; Sugita, K.; Nakazawa, S.; Kasugai, Y.; Ueda, R.; Seto, M. Genetic abnormalities involved in t(12;21) TELAML1 acute lymphoblastic leukemia: analysis by means of arraybased comparative genomic hybridization. Cancer Sci., 2007, 98, 698-706. [71] Webb, D.; Roberts, I.; Vyas, P. Haematology of Down syndrome. Arch. Dis. Child. Fetal Neonatal Ed., 2007, 92, F503- 507. [72] Zwaan, C.M.; Reinhardt, D.; Hitzler, J.; Vyas, P. Acute leukemias in children with Down syndrome. Hematol. Oncol. Clin. North Am., 2010, 24, 19-34. [73] Forestier, E.; Izraeli, S.; Beverloo, B.; Haas, O.; Pession, A.; Michalova, K.; Stark, B.; Harrison, C.J.; Teigler-Schlegel, A.; Johansson, B. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood, 2008, 111, 1575-1583.
URI:	http://wrap.warwick.ac.uk/id/eprint/5277